NCT00947856
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
PHASE2
COMPLETED
NCT00947856
INTERVENTIONAL
Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
Inclusion Criteria:
* Participated in a previous brentuximab vedotin study.
* CD30-positive hematologic malignancy.
* At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For retreatment, patients must have previously achieved either complete or partial remission with brentuximab vedotin and experienced disease progression after discontinuing the prior brentuximab vedotin study.
Exclusion Criteria:
Withdrew consent to participate in any prior brentuximab vedotin study.
Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
- TREATMENT
-
- Type: DRUG
- Name: brentuximab vedotin
- Description: Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
- Arm Group Labels: BV Extension, BV Retreatment
- Seagen Inc.